Blueprint Medicines, Inc. (BPMC)

Oncology Corporate Profile

Stock Performance

15.8900
-1.4200

HQ Location

215 First Street
Cambridge, MA 2142

Company Description

Blueprint Medicines makes kinase drugs to treat patients with genomically defined diseases. Led by a team of industry innovators, Blueprint Medicines integrates a novel target discovery engine and a proprietary compound library to understand the blueprint of cancer and craft highly selective therapies. This empowers the Blueprint Medicines team to develop patient-defined medicines aimed at eradicating cancer.

Website: http://www.blueprintmedicines.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
BLU-285_PDGFR__D842V inhibitorGastrointestinal Stromal Tumors (GIST)I
BLU-554PDGFR__D842V inhibitorHepatocellular carcinoma (HCC)I
BLU-667RET inhibitorNon Small Cell Lung Cancer (NSCLC)I
BLU-667RET inhibitorThyroid cancerI

Source


http://www.blueprintmedicines.com/

Recent News Headlines

Blueprint Medicines Announces Enrollment of First Patient in Phase 1 Clinical Trial for BLU-667

3/20/2017 08:00 pm

[PR Newswire] - CAMBRIDGE, Mass., March 20, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it has dosed the first patient in a Phase 1 clinical trial of BLU-667, an investigational RET inhibitor for patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other advanced solid tumors that harbor a RET alteration. "By rapidly initiating a clinical trial for our potent and selective RET inhibitor BLU-667, we have successfully achieved a key 2017 milestone," said Jeff Albers, Chief Executive Officer of Blueprint Medicines. "This continued progress underscores our commitment to build Blueprint Medicines into a sustainable company.

Blueprint Medicines Reports Fourth Quarter and Full Year 2016 Financial Results

3/9/2017 12:00 pm

[PR Newswire] - CAMBRIDGE, Mass., March 9, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ...

Blueprint Medicines to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, March 9, 2017

3/2/2017 01:00 pm

[PR Newswire] - CAMBRIDGE, Mass., March 2, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 9, 2017 to report its fourth quarter and full year 2016 financial results and provide a corporate update. A webcast of the call will also be available on the Investors section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

Blueprint Medicines to Present at Upcoming Investor Conferences in March

2/28/2017 01:00 pm

[PR Newswire] - CAMBRIDGE, Mass., Feb. 28, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ...

Blueprint Medicines to Present at 2017 RBC Capital Markets Global Healthcare Conference

2/15/2017 01:00 pm

[PR Newswire] - CAMBRIDGE, Mass., Feb. 15, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, ...